Perrigo Company plc (PRGO) reported adjusted earnings of 29 cents per share in the first quarter of 2024, beating the Zacks Consensus Estimate of 24 cents. Earnings were down 35.6% year over year, primarily due to a negative financial impact of 30 cents per share from infant formula. Net sales declined 8.4% year over year to $1.08 billion, missing the Zacks Consensus Estimate of $1.09 billion. The downside was due to lower net sales in infant formula and the negative impact of purposeful SKU prioritization ...

Perrigo (PRGO) reported $1.08 billion in revenue for the quarter ended March 2024, representing a year-over- year decline of 8.4%. EPS of $0.29 for the same period compares to $0.45 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $1.09 billion, representing a surprise of -0.91%. The company delivered an EPS surprise of +20.83%, with the consensus EPS estimate being $0.24. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street ...

EXHIBIT 99.1 Perrigo Reports First Quarter 2024 Financial Results From Continuing Operations Delivered Adjusted Diluted Earnings Per Share Results Above Projection, Due Primarily to Timing of Infant Formula Shipments; Reaffirm 2024 Financial Outlook Advanced Augmenting and Strengthening of Infant Formula Facilities, Recovery of Manufacturing Volumes Underway Progressed Blueprint to Build One Perrigo; On Target to Deliver Project Energize Goals; Announced Today in a Separate Press Release the Executive Trans ...

Delivered Adjusted Diluted Earnings Per Share Results Above Projection, Due Primarily to Timing of Infant Formula Shipments; Reaffirm 2024 Financial Outlook Advanced Augmenting and Strengthening of Infant Formula Facilities, Recovery of Manufacturing Volumes Underway Progressed Blueprint to Build One Perrigo; On Target to Deliver Project Energize Goals; Announced Today in a Separate Press Release the Executive Transition for the Consumer Self-Care International Business Recently Announced Plan to Divest HRA ...

Svend Andersen, EVP and President Consumer Self-Care International (CSCI), to Retire Roberto Khoury, a Global Branded Consumer Health Veteran, Appointed to Lead the Business DUBLIN, May 7, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that Svend Andersen, Executive Vice President and President, Consumer Self-Care International (CSCI), intends to retire from the Company in December of this year. Roberto Khoury, a consumer self-care v ...

The upcoming report from Perrigo (PRGO) is expected to reveal quarterly earnings of $0.24 per share, indicating a decline of 46.7% compared to the year-ago period. Analysts forecast revenues of $1.09 billion, representing a decrease of 7.6% year over year. The current level reflects an upward revision of 0.6% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period. Prio ...

DUBLIN, May 1, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.276 per share, payable on June 18, 2024, to shareholders of record on May 31, 2024. About Perrigo Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the- counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to ...

Perrigo Company plc (PRGO) is scheduled to report first-quarter 2024 results on May 7, before the opening bell. In the last reported quarter, the company posted an earnings surprise of 3.61%. Let’s see how things have shaped up for this announcement. Factors at Play The Zacks Consensus Estimate for Perrigo’s total revenues is pegged at around $1.1 billion, while the same for earnings stands at 24 cents per share. Both metrics indicate a decline from the year-ago quarter’s levels. Perrigo reports its results ...

Perrigo公司出售HRA Pharma Rare Diseases业务 - Perrigo公司宣布将出售HRA Pharma Rare Diseases业务给Esteve Healthcare，总交易金额高达275百万欧元，其中包括1.9亿欧元的现金支付和最多8500万欧元的潜在奖励[1] - 出售HRA Pharma Rare Diseases业务将有助于Perrigo公司降低净杠杆率至2024年底低于4.0倍[2] ESTEVE公司收购HRA Rare Diseases业务 - ESTEVE公司将受益于收购HRA Rare Diseases业务，这一交易旨在满足未满足的患者需求，符合ESTEVE公司改善人们生活的宗旨[2] 财务顾问和法律顾问 - Morgan Stanley & Co. LLC担任Perrigo的财务顾问，Wachtell, Lipton, Rosen & Katz担任其法律顾问；Perella Weinberg Partners担任ESTEVE的财务顾问，Clifford Chance担任其法律顾问[3] Perrigo公司介绍 - Perrigo公司是一家领先的消费者自我护理产品提供商，致力于增强个人福祉，通过赋予消费者主动预防或治疗可自我管理的疾病来实现这一目标[4]

公司业绩 - Perrigo公司计划于2024年5月7日发布第一季度财务业绩[1] - 财报电话会议将通过网络直播和电话方式提供[2] 公司背景 - Perrigo公司是一家领先的消费者自我护理产品提供商[3] 风险和不确定因素 - 公司在未来展望声明中提到了一些风险和不确定因素[4]